SureSelect Cancer Research Pan Heme

RUO

SureSelect Cancer Research Pan Heme is a set of hybrid capture-based next-generation sequencing (NGS) panels that interrogates both DNA and RNA to deliver comprehensive genomic profiling for hematologic cancer research. The panels were developed in collaboration with leading researchers at Roswell Park Comprehensive Cancer Center.

The complete solution includes SureSelect probes and reagents or Magnis SureSelect kits, paired with optimized software for accurate variant calling and reporting. This end-to-end solution delivers rapid turnaround times through a scalable, automated workflow that’s cost-effective and easy to implement.

For Research Use Only. Not for use in diagnostic procedures.

Cancer

Features

Expertly Curated Content. Panel content thoughtfully curated by world-renowned experts in hematologic cancer research at Roswell Park Comprehensive Cancer Center (Buffalo, New York).
Comprehensive Profiling. Integrated DNA/RNA analysis that detects all classes of genomic alterations – SNVs, indels, CNVs, FLT3-ITDs, KMT2A PTDs, IGH/K/L rearrangements, and gene fusions.
Rapid, Turnkey Solution. 48-hour turnaround time from sample to report, leveraging fully automated NGS library preparation and target enrichment, as well as variant analysis and reporting.
Easy Implementation. Simple and cost-effective in-house implementation powered by Magnis automation and optimized QCI software from QIAGEN.
Complete Control. Full control of samples, budget, sequencing data, and turnaround time by establishing in-house comprehensive genomic profiling for hematologic cancer research.

Specifications


Automation Compatible	Yes
Hybridization Time	90-minute

Return to top

Featured

SureSelect Cancer Research Pan Heme

Product Details

Integrated Long-Read Target Enrichment and Comprehensive Genomic Profiling for Hematologic Malignancies Using the SureSelect Cancer Research Pan Heme Panel

Customers Also Viewed These Products